Search

Search Results

• Efficacy and safety of adalimumab biosimilar GP2017 in a 24-month treatment period for plaque psoriasis: real-life experience from Emilia-Romagna centers, Italy

  Marco May Lee, Vito Di Lernia, Francesca Peccerillo, Federico Bardazzi, Michela Tabanelli, Michela Ricci, Davide Melandri, Monica Corazza, Francesca Satolli, Andrea Conti

  01-07-2025

  https://doi.org/10.4081/dr.2025.10315

  618

  PDF: 314

  HTML: 22
• 

  Mycobacterium kansasii infection in a psoriasis patient treated with adalimumab and switch to apremilast: First report and literature review

  Alexandra Maria Giovanna Brunasso, Sanja Javor, Emanuele Pontali, Simona Sola, Cesare Massone

  29-07-2021

  https://doi.org/10.4081/dr.2021.8797

  3151

  PDF: 666

  HTML: 18

• CD4/CD8 double-negative mycosis fungoides: a review

  Khalid Nabil Nagshabandi, Abdulrahman Shadid, Asem Shadid, Nouf K. Almuhanna

  12-04-2024

  https://doi.org/10.4081/dr.2024.9908

  3314

  PDF: 656

  SUPPLEMENTARY: 128

  HTML: 36
• 

  Efficacy of adalimumab in moderate to severe hidradenitis suppurativa: Real life data

  Aikaterini Kyriakou, Anastasia Trigoni, Nikiforos Galanis, Dimitrios Sotiriadis, Aikaterini Patsatsi

  01-10-2018

  https://doi.org/10.4081/dr.2018.7859

  2082

  PDF: 1088

  HTML: 83

• Adalimumab-induced facial erysipelas and its successful resolution with azithromycin in a 19-year-old female

  Caterina Mariarosaria Giorgio, Anna Balato, Gaetano Licata, Giuseppe Argenziano, Vittorio Tancredi, Eugenia Veronica Di Brizzi

  21-02-2025

  https://doi.org/10.4081/dr.2025.10278

  496

  PDF: 325

  HTML: 22
• 

  Erythrodermic psoriasis treated with apremilast

  John Arcilla, Daniel Joe, Johnathan Kim, Yohanan Kim, VuAnh N. Truong, Navin Jaipaul

  19-09-2016

  https://doi.org/10.4081/dr.2016.6599

  2201

  PDF: 989

  HTML: 609
• 

  Photocarcinogenicity of selected topically applied dermatological drugs: calcineurin inhibitors, corticosteroids, and vitamin D analogs

  Catharina Margrethe Lerche, Hans Christian Wulf

  e13

  14-09-2010

  https://doi.org/10.4081/dr.2010.e13

  2213

  PDF: 882

  HTML: 180
• 

  A case of squamous cell carcinoma arising in a giant porokeratosis previously diagnosed as psoriasis

  Lorry Aitkens, Joel Byrne, Charay Jennings-Dover, Kathryn Anne Potter

  29-12-2022

  https://doi.org/10.4081/dr.2023.9634

  969

  PDF: 493

  HTML: 126

• Natural language processing of online support group postings reveals patients’ perspectives on strategies for managing psoriasis

  Karan Rajalingam, Phillip M. Johansen, Nicole J. Levin, Jerry Qi, Oge Marques

  11-09-2023

  https://doi.org/10.4081/dr.2023.9824

  1000

  PDF: 965

  HTML: 40

• Severe relapse of generalized psoriasis in a young patient with a Löfgren syndrome history

  Ermira Ziçishti, Migena Vargu, Sabina Dedej, Eriselda Kurushi, Valbona Zenelaj, Ermira Vasili

  13-03-2025

  https://doi.org/10.4081/dr.2025.10021

  516

  PDF: 343

  HTML: 14

• Skin-directed therapy and biologic response modifiers in mycosis fungoides

  Vieri Grandi, Virginia Alba Colantuono, Nicola Pimpinelli

  07-05-2024

  https://doi.org/10.4081/dr.2024.9926

  623

  PDF: 598

• Acute generalized exanthematous pustulosis triggered by dupilumab

  Caterina Mariarosaria Giorgio, Gaetano Licata, Giuseppe Argenziano, Vittorio Tancredi, Anna Balato, Eugenia Veronica Di Brizzi

  23-07-2025

  https://doi.org/10.4081/dr.2025.10219

  523

  PDF: 348

  HTML: 26
• 

  Measuring the impact of pruritus in patients with epidermolysis bullosa: evaluation with an itch-specific instrument

  Ashjan Alheggi, Raneem Alnutaifi, Manal Alkhonezan, Norah Almudawi, Renad Alsuhaibani, Philip Moons, Turki Aljuhani

  18-05-2023

  https://doi.org/10.4081/dr.2023.9700

  1204

  PDF: 395

  APPENDIX S1: 207

  HTML: 17
• 

  Exacerbation of generalized plaque psoriasis after tuberculin test

  Alberto Corrà, Lavinia Quintarelli, Alice Verdelli, Walter Volpi, Marzia Caproni

  28-07-2021

  https://doi.org/10.4081/dr.2021.9019

  3206

  PDF: 529

  HTML: 301
• 

  Association of single-nucleotide NR3C1 gene polymorphisms with glucocorticosteroid responsiveness in patients with pemphigus vulgaris

  Thai Van Thanh Le, Duy Quan Nguyen, Ngoc Dang Tran, Hoang Kim Tu Trinh

  05-10-2021

  https://doi.org/10.4081/dr.2021.9190

  4197

  PDF: 573

  HTML: 14

• Efficacy and safety of risankizumab in patients with erythrodermic and sub-erythrodermic psoriasis: a case series

  Andrea D'Arino, Maria Concetta Fargnoli, Pasquale Frascione, Chiara Assorgi, Annunziata Dattola, Viviana Lora, Matteo Megna, Flavia Pigliacelli, Emanuele Vagnozzi, Diego Orsini

  30-07-2025

  https://doi.org/10.4081/dr.2025.10379

  562

  PDF: 381

  HTML: 11

• 29 | INNOVATIVE THERAPEUTIC STRATEGIES IN GENODERMATOSIS: AN ITALIAN MULTICENTRE STUDY F. Pavan¹, F. Cassalia², S. Giordano³, A. Gelmetti⁴, L. Ventura⁵, F. Caroppo², A. Bassi⁶, F. Martorana⁷, R. Balestri⁸, A. Guglielmo⁹, F. Ambrogio¹⁰, A. Bonvicino³, I. Neri⁴, P. Quaglino³, A. Belloni Fortina¹¹ | ¹Pediatrics Unit, Department of Women’s and Child’s Health (SDB), University of Padua, Italy; ²Dermatology Unit, Department of Medicine (DIMED), University of Padua, Italy; ³Department of Medical Sciences, Section of Dermatology, University of Turin, Italy; ⁴Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Italy; ⁵Department of Statistical Science, University of Padua, Italy; ⁶Unit of Dermatology, Azienda USL Toscana Nord Ovest, Lucca, Italy; ⁷Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II; ⁸Division of Dermatology, Outpatient Consultation for Rare Diseases, APSS, Trento, Italy; ⁹Institute of Dermatology, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy; ¹⁰Section of Dermatology and Venereology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari “Aldo Moro”, Italy; ¹¹Pediatric Dermatology Department of Women’s and Child’s Health (SDB), University of Padua, Italy

  Associazione Dermatologi-Venereologi Ospedalieri Italiani e della Sanità Pubblica

  24-09-2026

  https://doi.org/10.4081/dr.2026.11091

  0

  PDF: 0

• Does the response to bimekizumab vary according to previous therapy with methotrexate versus cyclosporine?

  Ilaria Salvi, Alexandra M. G. Brunasso, Franco Castelli, Andrea Michelerio, Paolo Pella, Marco Rubatto, Paolo Dapavo, Emanuele Cozzani, Martina Burlando

  20-03-2026

  https://doi.org/10.4081/dr.2026.10236

  332

  PDF: 271

• 67 | LEBRIKIZUMAB FOR PAEDIATRIC PATIENTS AGED ≥6 MONTHS WITH MODERATE-TO-SEVERE AD: PHASE 3 ADORABLE-1 WEEK-16 RESULTS L. Stingeni¹, L. Eichenfield², J. Ornelas³, V. Prajapati⁴, C. Yang⁵, A. Tanaka⁶, S. Weidinger⁷, C. Flohr⁸, E. Swanson⁹, L. Martin¹⁰, S. Daveiga¹¹, R. Gontijo Lima¹¹, H. Elmaraghy¹¹, E. Pierce¹¹, P. Sen¹¹, G. Gallo¹¹, M. Piruzeli¹¹, A. Larkin¹¹, M. Grau¹², Y. Mihaylov¹², A. Paller¹³ | ¹Dermatology Section, Department of Medicine and Surgery, University of Perugia, Italy; ²Departments of Dermatology and Pediatrics, University of California San Diego School of Medicine, La Jolla, California, USA; ³Department of Dermatology, Integrative Skin Science and Research, Sacramento, California, USA; ⁴Dermatology Research Institute, Skin Health & Wellness Centre, Probity Medical Research, and University of Calgary, Calgary, Canada; ⁵Chang Gung University College of Medicine, Taoyuan, Taiwan; ⁶Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan; ⁷Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Lübeck, Germany; ⁸Department of Dermatology and Population Health Sciences, King’s College London, UK; ⁹Ada West Dermatology, St Luke’s Children’s Hospital Idaho, USA; ¹⁰School of Clinical Medicine, UNSW Sydney & Dermatology Department, Sydney Children’s Hospital, Sydney, Australia; ¹¹Eli Lilly and Company, Indianapolis, Indiana, USA; ¹²Almirall R&D, S.A., Barcelona, Spain; ¹³Dermatology and Infectious Disease, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA

  Associazione Dermatologi-Venereologi Ospedalieri Italiani e della Sanità Pubblica

  24-09-2026

  https://doi.org/10.4081/dr.2026.11114

  0

  PDF: 0

• Appearance of alopecia areata during treatment with tildrakizumab for severe palmoplantar psoriasis

  Davide Bertolla, Andrea Conti

  30-01-2026

  https://doi.org/10.4081/dr.2026.10240

  1010

  PDF: 407
• 

  Certolizumab to treat hidradenitis suppurativa

  Asem Shadid, Saud Alobaida, Yousef Binamer

  27-10-2022

  https://doi.org/10.4081/dr.2022.9566

  1979

  PDF: 753

  HTML: 53

• Upadacitinib as a potential option for the management of paradoxical eczema induced by interleukin-23 inhibitors

  Anna Paola Lugli, Niccolò Gori, Elena Ippoliti, Benedetta Ambrosio, Ketty Peris

  03-02-2026

  https://doi.org/10.4081/dr.2026.10644

  733

  PDF: 472
• 

  Guselkumab for the treatment of severe plaque psoriasis in a schizophrenia patient

  Nicoletta Bernardini, Nevena Skroza, Elisabeth Prevete, Federica Marraffa, Ilaria Proietti, Ersilia Tolino, Alessandra Mambrin, Giovanni Rossi, Salvatore Volpe, Giuseppe Bersani, Concetta Potenza

  23-11-2022

  https://doi.org/10.4081/dr.2022.9476

  1518

  PDF: 512

  HTML: 32

• A study on tumor necrosis factor-α single nucleotide polymorphisms and psoriasis vulgaris in Vietnam

  Vinh Ngo Minh, Thiên Phúc Lý, Hao Nguyen Trong, Chuong Nguyen Hoang

  12-04-2024

  https://doi.org/10.4081/dr.2024.9899

  1007

  PDF: 623

  HTML: 31
• 

  Environmental factors in autoimmune bullous diseases with a focus on seasonality: new insights

  Roberto D'Astolto, Lavinia Quintarelli, Alberto Corrà, Marzia Caproni, Luca Fania, Giovanni Di Zenzo, Biagio Didona, Giulia Gasparini, Emanuele Cozzani, Claudio Feliciani

  14-06-2023

  https://doi.org/10.4081/dr.2023.9641

  1077

  PDF: 510

  HTML: 32